Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - POINT Biopharma Global Inc. | tm219698d3_ex10-1.htm |
| EX-2.1 - EXHIBIT 2.1 - POINT Biopharma Global Inc. | tm219698d3_ex2-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 16 , 2021 (March 15, 2021)
THERAPEUTICS ACQUISITION CORP.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39311 | 85-0800493 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
|
200 Berkeley Street, 18th Floor Boston, MA |
02116 | |
| (Address of principal executive offices) | (Zip Code) |
(617) 778.2540
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbols |
Name of each exchange on which registered | ||
| Class A common stock, par value $0.0001 per share | RACA | The Nasdaq Stock Market LLC |
| x | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| ¨ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
Explanatory Note
This Amendment supplements Item 9.01 (solely to add additional exhibits) of the Current Report on Form 8-K of Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (the “Company”), filed with the Securities and Exchange Commission on March 15, 2021 (the “Original Current Report”), in which the Company reported, among other events, the execution of the Business Combination Agreement (as defined in the Original Current Report). Item 1.01, Item 3.02, and Item 7.01 of the Original Current Report remain unchanged. Interested parties should refer to the Original Current Report for Item 1.01, Item 3.02, and Item 7.01 and the prior exhibits filed pursuant to Item 9.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| * | Certain exhibits and schedules to this Exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Therapeutics Acquisition Corp. | ||
| By: | /s/ Matthew Hammond | |
| Name: Matthew Hammond | ||
| Title: Chief Financial Officer | ||
Dated: March 16, 2021